Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects

References

• Giustina A, Mazziotti G, Maffezzoni F, et al. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. Expert Opin Investig Drugs. 2014;23:1619–1635.
   PubMed Web of Science ®Google Scholar
• Leoncini E, Boffetta P, Shafir M, et al. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine. 2017. DOI: 10.1007/s12020-017-1273-x.
   PubMed Web of Science ®Google Scholar
• Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342.
   PubMed Web of Science ®Google Scholar
• Tamagno G, Sheahan K, Skehan SJ, et al. Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor. Endocrine. 2013;44:504–509.
   PubMed Web of Science ®Google Scholar
• Alexandraki KI, Kaltsas G. Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. Endocrine. 2012;41:40–52.
   PubMed Web of Science ®Google Scholar
• Klimstra DS, Arnold R, Capella C, et al. WHO classification of tumours of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC; 2010.
   Google Scholar
• Milione M, Fazio N. G3 GEP NENs category: are basic and clinical investigations well integrated? Endocrine. 2017. DOI:10.1007/s12020-017-1365-7
   Web of Science ®Google Scholar
• Klimstra DS. Reassessing the grade of gastroenteropancreatic neuroendocrine neoplasms. Endocrine. 2016;53:4–6.
   PubMed Web of Science ®Google Scholar
• Richards-Taylor S, Ewings SM, Jaynes E, et al. The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis. J Clin Pathol. 2016;69:612–618.
   PubMed Web of Science ®Google Scholar
• Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072.
   PubMed Web of Science ®Google Scholar
• Öberg K. Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors? Endocrine. 2012;42:3–4.
   PubMed Web of Science ®Google Scholar
• Treglia G, Castaldi P, Rindi G, et al. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012;42:80–87.
   PubMed Web of Science ®Google Scholar
• Guillemin R. Peptides in the brain: the new endocrinology of the neuron. Science. 1978;202:390–402.
   PubMed Web of Science ®Google Scholar
• Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev. 1995;16:427–442.
   PubMed Web of Science ®Google Scholar
• Seger R, Krebs EG. The MAPK signaling cascade. Faseb J. 1995;9:726–735.
   PubMed Web of Science ®Google Scholar
• Rocheville M, Lange DC, Kumar U, et al. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem. 2000;275:7862–7869.
   PubMed Web of Science ®Google Scholar
• Grant M, Alturaihi H, Jaquet P, et al. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol. 2008;22:2278–2292.
   PubMed Web of Science ®Google Scholar
• Adams RL, Adams IP, Lindow SW, et al. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer. 2005;92:1493–1498.
   PubMed Web of Science ®Google Scholar
• Patel PC, Barrie R, Hill N, et al. Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery. 1994;116:1148–1152.
   PubMed Web of Science ®Google Scholar
• Badway AC, Blake AD. Somatostatin: a hormone for the heart? Curr Vasc Pharmacol. 2005;3:125–131.
   PubMedGoogle Scholar
• Morini M, Villa V, Arena S, et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology. 2003;144:1574–1584.
   PubMed Web of Science ®Google Scholar
• Kvols LK, Woltering EA. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs. 2006;17:601–608.
   PubMed Web of Science ®Google Scholar
• Lamberts SW, van der Lely AJ, de Herder WW, et al. Octreotide. N Engl J Med. 1996;334:246–254.
   PubMed Web of Science ®Google Scholar
• Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012;366:914–924.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:875–884.
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad, somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146:707–716.
   PubMed Web of Science ®Google Scholar
• Wulbrand U, Wied M, Zofel P, et al. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest. 1998;28:1038–1049.
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Vandamme T, Albertelli M, et al. Hormone and receptor candidates for target and biotherapy of neuroendocrine tumors. Front Horm Res. 2015;44:216–238.
   PubMed Web of Science ®Google Scholar
• Kvols LK, Moertel CG, O’Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315:663–666.
   PubMed Web of Science ®Google Scholar
• Wild D, Christ E, Caplin ME, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med. 2011;52:1412–1417.
   PubMed Web of Science ®Google Scholar
• Vezzosi D, Bennet A, Rochaix P, et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol. 2005;152:757–767.
   PubMed Web of Science ®Google Scholar
• Scarpignato C. The place of octreotide in the medical management of the dumping syndrome. Digestion. 1996;57:114–118.
   PubMed Web of Science ®Google Scholar
• Kimbara S, Fujiwara Y, Toyoda M, et al. Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide. Clin J Gastroenterol. 2014;7:255–259.
   PubMedGoogle Scholar
• Wei J, Lin S, Wang C, et al. Glucagonoma syndrome: a case report. Oncol Lett. 2015;10:1113–1116.
   PubMed Web of Science ®Google Scholar
• Angeletti S, Corleto VD, Schillaci O, et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut. 1998;42:792–794.
   PubMed Web of Science ®Google Scholar
• Schwartz CJ, Kimberg DV, Sheerin HE, et al. Vasoactive intestinal peptide stimulation of adenylate cyclase and active electrolyte secretion in intestinal mucosa. J Clin Invest. 1974;54:536–544.
   PubMed Web of Science ®Google Scholar
• Kamp K, Feelders RA, Van Adrichem RC, et al. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up. J Clin Endocrinol Metab. 2014;99:3060–3069.
   PubMed Web of Science ®Google Scholar
• Tulipano G, Stumm R, Pfeiffer M, et al. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem. 2004;279:21374–21382.
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24:28–47.
   PubMed Web of Science ®Google Scholar
• Cambiaghi V, Vitali E, Morone D, et al. Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line. Endocrine. 2017;56:146–157.
   PubMed Web of Science ®Google Scholar
• Eriksson B, Öberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol. 1999;10:S31–S38.
   PubMed Web of Science ®Google Scholar
• Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–4663.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–233.
   PubMed Web of Science ®Google Scholar
• Clark OH, Benson AB 3rd, Berlin JD, et al. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009;7:712–747.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–216.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Ćwikła JB, et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016;23:191–199.
   PubMed Web of Science ®Google Scholar
• Campana D, Ravizza D, Ferolla P, et al. Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. Endocrine. 2017;56:633–638.
   PubMed Web of Science ®Google Scholar
• Ono K, Suzuki T, Miki Y, et al. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727. Anticancer Res. 2007;27:2231–2239.
   PubMed Web of Science ®Google Scholar
• Kidd M, Drozdov I, Joseph R, et al. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer. 2008;113:690–700.
   PubMed Web of Science ®Google Scholar
• Domvri K, Bougiouklis D, Zarogoulidis P, et al. Could somatostatin enhance the outcomes of chemotherapeutic treatment in SCLC? J Cancer. 2015;6:360–366.
   PubMed Web of Science ®Google Scholar
• Sullivan I, Le Teuff G, Guigay J, et al. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. Eur J Cancer. 2017;75:259–267.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26:1604–1620.
   PubMed Web of Science ®Google Scholar
• Pavel M, O’Toole D, Costa F, et al. Consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms –NEN- and NEN of unknown primary site. Neuroendocrinology. 2016;103-2:172–185.
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: neuroendocrine tumors. Version 3.2017; www.nccn.org/professionals/physician
   Google Scholar
• Mazziotti G, Floriani I, Bonadonna S, et al. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009;94:1500–1508.
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Porcelli T, Bogazzi F, et al. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol. 2011;164:341–347.
   PubMed Web of Science ®Google Scholar
• Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol. 2009;161:331–338.
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Cannavò S, et al. High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J Clin Endocrinol Metab. 2017 Apr 17. 10.1210/jc.2017-00142.
   PubMed Web of Science ®Google Scholar
• Woltering EA, Mamikunian PM, Zietz S, et al. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas. 2005;31:392–400.
   PubMed Web of Science ®Google Scholar
• Chan DL, Ferone D, Albertelli M, et al. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. Endocrine. 2017.  DOI:10.1007/s12020-017-1360-z.
   Web of Science ®Google Scholar
• Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol. 2004;151:107–112.
   PubMed Web of Science ®Google Scholar
• Imam H, Eriksson B, Lukinius A, et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol. 1997;36:607–614.
   PubMed Web of Science ®Google Scholar
• Yim KL. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. Endocrine. 2011;40:181–186.
   PubMed Web of Science ®Google Scholar
• Kolby L, Persson G, Franzen S, et al. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg. 2003;90:687–693.
   PubMed Web of Science ®Google Scholar
• Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3:761–771.
   PubMed Web of Science ®Google Scholar
• Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors–the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21:2689–2696.
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–523.
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–513.
   PubMed Web of Science ®Google Scholar
• Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28:69–76.
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, et al. Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378:2005–2012.
   PubMed Web of Science ®Google Scholar
• Pusceddu S, Verzoni E, Prinzi N, et al. Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. Ther Adv Med Oncol. 2017;9:183–188.
   PubMed Web of Science ®Google Scholar
• Mohamed A, Romano D, Saveanu A, et al. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs? Oncotarget. 2017;8:41044–41063.
   PubMed Web of Science ®Google Scholar
• Cives M, Strosberg J, Coppola D. PD1 and PDL1 expression in midgut neuroendocrine tumors. Neuroendocrinology. 2016;103:36–37.
   Web of Science ®Google Scholar
• Kim ST, Ha SY, Lee S, et al. The impact of PD-L1 expression in patients with metastatic GEP-NETs. Journal of Cancer. 2016;7:484–489.
   PubMed Web of Science ®Google Scholar
• Lesche S, Lehmann D, Nagel F, et al. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab. 2009;94:654–661.
   PubMed Web of Science ®Google Scholar
• Mohamed A, Blanchard MP, Albertelli M, et al. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. Endocr Relat Cancer. 2014;21:691–704.
   PubMed Web of Science ®Google Scholar
• Kvols L, Wiedenmann B, Oberg K, et al. The SOM230 Carcinoid Study Group. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study. ASCO GI Cancers Symposium 2006; abstr 171.
   Google Scholar
• Kvols LK, Oberg KE, O’Dorisio TM, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012;19:657–666.
   PubMed Web of Science ®Google Scholar
• Wolin EM, Jarzab B, Eriksson B, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075–5086.
   PubMed Web of Science ®Google Scholar
• Yao JC, Chan JA, Mita AC, et al. Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors. Onco Targets Ther. 2017;10:3177–3186.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Ruszniewski P, Van Cutsem E, et al. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol. 2017;28:1309–1315.
   PubMed Web of Science ®Google Scholar
• Ferolla P, Brizzi MP, Meyer T, et al. Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: results from the randomized, phase 2 LUNA study. Ann Oncol. 2016;27(Suppl 6):vi145. abstr #4180.
   Google Scholar
• Ramundo V, Del Prete M, Marotta V, et al. Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. Clin Endocrinol. 2014;80:850–855.
   PubMed Web of Science ®Google Scholar
• Walls GV, Stevenson M, Soukup BS, et al. Pasireotide therapy of multiple endocrine neoplasia type 1-associated neuroendocrine tumors in female mice deleted for an Men1 allele improves survival and reduces tumor progression. Endocrinology. 2016;157:1789–1798.
   PubMed Web of Science ®Google Scholar
• Kidd M, Modlin IM, Black JW, et al. A comparison of the effects of gastrin, somatostatin and dopamine receptor analogs on rat gastric enterochromaffin-like cell secretion and proliferation. Regul Pept. 2007;143:109–117.
   PubMed Web of Science ®Google Scholar
• Van Adrichem RC, De Herder WW, Kamp K, et al. Effects of somatostatin analogs and dopamine agonists on insulin-like growth factor 2-induced insulin receptor isoform A activation by gastroenteropancreatic neuroendocrine tumor cells. Neuroendocrinology. 2016;103:815–825.
   PubMed Web of Science ®Google Scholar
• Couvelard A, Pélaprat D, Dokmak S, et al. Antisecretory effects of chimeric somatostatin/dopamine receptor ligands on gastroenteropancreatic neuroendocrine tumors. Pancreas. 2017;46:631–638.
   PubMed Web of Science ®Google Scholar
• O’Toole D, Saveanu A, Couvelard A, et al. The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol. 2006;155:849–857.
   PubMed Web of Science ®Google Scholar
• Bodei L, Kwekkeboom DJ, Kidd M, et al. Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer. Semin Nucl Med. 2016;46:225–238.
   PubMed Web of Science ®Google Scholar
• Brabander T, Teunissen JJ, Van Eijck CH, et al. Peptide receptor radionuclide therapy of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2016;30:103–114.
   PubMed Web of Science ®Google Scholar
• Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–135.
   PubMed Web of Science ®Google Scholar
• Fani M, Nicolas GP, Wild D. Somatostatin receptor antagonists for imaging and therapy. J Nucl Med. 2017 Sep;58(Suppl 2):61S–66S.
   PubMed Web of Science ®Google Scholar
• Dalm SU, Nonnekens J, Doeswijk GN, et al. Comparison of the therapeutic response to treatment with a 177 Lu-labeled somatostatin receptor agonist and antagonist in preclinical models. J Nucl Med. 2016;57:260–265.
   PubMed Web of Science ®Google Scholar
• Nicolas GP, Mansi R, McDougall L, et al. Biodistribution, pharmacokinetics and dosimetry of 177 Lu-, 90 Y- and 111 In-labeled somatostatin receptor antagonist OPS201 in comparison to the agonist 177 Lu-DOTA-TATE: the mass effect. J Nucl Med. 2017;58:1435–1441.
   PubMed Web of Science ®Google Scholar
• Beykan S, Dam JS, Eberlein U, et al. 177 Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model. EJNMMI Res. 2016;6:50.
   PubMed Web of Science ®Google Scholar
• Wild D, Fani M, Fischer R, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248–1252.
   PubMed Web of Science ®Google Scholar
• Rinke A, Wittenberg M, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide Lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology. 2017;104:26–32.
   PubMed Web of Science ®Google Scholar
• Merola E, Panzuto F, Delle Fave G. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Oncotarget. 2017;8:46624–46634.
   PubMed Web of Science ®Google Scholar
• Janson ET, Westlin JE, Eriksson B, et al. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol. 1994;131:577–581.
   PubMed Web of Science ®Google Scholar
• Janson ET. Treatment of neuroendocrine tumors with somatostatin analogs. Pituitary. 2006;9:249–256.
   PubMedGoogle Scholar
• Deroose CM, Hindié E, Kebebew E, et al. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med. 2016;57:1949–1956.
   PubMed Web of Science ®Google Scholar
• Hillman N, Herranz L, Alvarez C, et al. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan). Exp Clin Endocrinol Diabetes. 1998;106:226–230.
   PubMed Web of Science ®Google Scholar
• Niederle B, Pape UF, Costa F, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103:125–138.
   PubMed Web of Science ®Google Scholar
• Fotouhi O, Kjellin H, Larsson C, et al. Proteomics suggests a role for APC-survivin in response to somatostatin analog treatment of neuroendocrine tumors. J Clin Endocrinol Metab. 2016;101:3616–3627.
   PubMed Web of Science ®Google Scholar
• Veenstra MJ, Van Koetsveld PM, Dogan F, et al. Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. Oncotarget. 2016. DOI:10.18632/oncotarget.9462.
   PubMed Web of Science ®Google Scholar
• Taelman VF, Radojewski P, Marincek N, et al. Upregulation of key molecules for targeted imaging and therapy. J Nucl Med. 2016;57:1805–1810.
   PubMed Web of Science ®Google Scholar